Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
about
Do bisphosphonates cause femoral insufficiency fractures?Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) projectAmerican Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures.Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures.Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data.Atypical Femoral Shaft Fractures in Female Bisphosphonate Users Were Associated with an Increased Anterolateral Femoral Bow and a Thicker Lateral Cortex: A Case-Control StudyLong-Term Alendronate Use Not without Consequences?Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study.The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronateBisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Diagnosis and management of mineral metabolism in CKD.Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails.Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acidAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisEmerging therapeutic opportunities for skeletal restoration.Osteoporosis and gastrointestinal disease.Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportAbsence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fracturesAdherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.Bone disease in HIV infection: a practical review and recommendations for HIV care providers.Sex and gender considerations in male patients with osteoporosisA phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study.Diseases affecting bone quality: beyond osteoporosis.Bilateral femoral insufficiency fractures likely related to long-term alendronate therapyRisk communication methods in hip fracture prevention: a randomised trial in primary careTrends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjectsLong-term safety concerns of antiresorptive therapy.Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case reportThe effect of long-term alendronate treatment on cortical thickness of the proximal femur.Atypical femoral fractures and bisphosphonate use: current evidence and clinical implicationsBilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report.Likelihood Ratio Test for Excess Homozygosity at Marker Loci on X Chromosome.Management of atypical femoral fracture: a scoping review and comprehensive algorithm.Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management
P2860
Q27021396-1D544302-BD40-4923-97A7-4D03CD47A553Q27026618-DE2EB0E2-C35D-49CA-9DFF-5AAC3C0ED062Q27027254-CB95DB6D-9A79-4B47-BF14-C100E6BA404AQ27693845-1A9ABB4B-CB4B-441C-A820-769CCB4E5F2DQ31026858-17676ED5-2A24-4152-AC63-32938C7C0BBFQ33552108-25B25390-6FDF-4283-88C1-528572D38F6EQ33633821-C052509C-CA79-4AE6-B147-87A91A0D0D4BQ33665130-F8B587FD-D035-440E-8FF7-0D5E80F90D7EQ33681406-A07E836B-0DC7-40ED-B872-4F48B6D85673Q33700394-422D0D80-D0C1-42E5-8F28-0FC6D82630A8Q33715141-7C4C21D6-654D-48F2-923F-2CEDD271A184Q33898681-925D6D8C-77B4-4108-A937-9A3CFFCB03E0Q33898842-50BD2E18-83EA-44B2-99CF-50113288A361Q33958113-A71096D7-4C6E-4FB4-B898-96879A0919C6Q33984172-E1914D90-0D28-422F-9CA1-3E6A73CDBD0BQ34084792-0595387F-D5D6-41BA-9C00-F8758EF8BDFEQ34158441-9246BEF4-F2D7-46B0-A966-C8C8D1D6C1D9Q34161867-9F3327D3-83AA-44B5-8C0A-CD8BB8008520Q34178759-DACA12A9-AD03-429B-AFC6-3860D8317392Q34189582-ED81E991-8497-4D53-B16B-4E933FF855C1Q34283690-6CFB406D-CE1D-4F34-9846-C692886FFD4CQ34486831-06D218B9-E0D5-411E-88C3-7CE2FD2B9667Q34599156-20CC3ED1-09B7-4D0C-832A-6035B51D39E6Q34626680-433EBEA0-BBFA-4A0F-BC37-78859F507A5EQ35019051-8EA3AACE-31CD-4F3F-AA7F-246A41539BDFQ35036493-1EA992A8-B22D-4FE1-BF18-748BDDB87856Q35050731-3594D1E1-96EC-4F6F-99B5-866DC64B5C71Q35078847-A504606F-8D2C-49D7-B7C8-6475F6BFCBE4Q35101976-526DAB44-9BFE-4893-BED2-AE8FC55AAA58Q35133542-044DE0C9-11BF-4C0B-9A2D-34208CFE4E08Q35229889-5442A229-FB19-4961-A1A4-82A84CF7604DQ35566438-864AF06D-E55E-42CE-B8D7-2338F69572B1Q35570961-3CC6189B-02A5-4DC0-8143-6358750F2F29Q35606133-EDB07E6A-B594-46E8-97AA-7C2F0BAA690AQ35613775-95698CF3-6ED7-4F4D-A770-22723F7D3327Q35780856-D5C7EACF-0445-40FB-B882-E3CCD64308CFQ35799470-69719F33-1403-403F-A6B2-0B8E610D7311Q35869871-BE9FDEA5-1C48-4B0E-A04D-53822EB1D8F4Q36027214-0180F0F9-56BC-4D30-AE45-CA4C52F6C11EQ36059397-DBD62858-30A4-4571-8259-0F3EDFCAA13B
P2860
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Association of low-energy femo ...... ate use: a case control study.
@ast
Association of low-energy femo ...... ate use: a case control study.
@en
type
label
Association of low-energy femo ...... ate use: a case control study.
@ast
Association of low-energy femo ...... ate use: a case control study.
@en
prefLabel
Association of low-energy femo ...... ate use: a case control study.
@ast
Association of low-energy femo ...... ate use: a case control study.
@en
P2093
P2860
P1476
Association of low-energy femo ...... ate use: a case control study.
@en
P2093
A S Neviaser
B A Lenart
D G Lorich
F Edobor-Osula
P2860
P2888
P304
P356
10.1007/S00198-008-0805-X
P407
P577
2008-12-09T00:00:00Z